Pharmako Biotechnologies Announces Regulatory Approval from Australian Therapeutic Goods Administration

Pharmako Biotechnologies, an authority in scientific research and development of specialty technologies, announced today that it has received approval for its manufacturing facility from the Therapeutic Goods Administration (TGA), Department of Health and Aging for the Government of Australia. Under the guidance of the TGA, Pharmako is now the first licensed manufacturer in Australia for the production of Active Pharmaceutical Ingredients (APIs) with advanced dispersion and solubility technologies, which includes its pre-mixes, capsules, liquids and powders.

“We are pleased to have received TGA approval for our facility in Australia,” said Pharmako’s co-founder and commercial director, Eric Meppem. “Given the stringent requirements of the TGA for the manufacturing of APIs, we feel even more confident in our ability to exceed the quality assurance demands of our customers.”
TGA approval represents a significant achievement for Pharmako, demonstrating that good manufacturing practices are established and in compliance. The approval places Pharmako within a select group of manufacturers which have the ability to meet and exceed rigorous evaluation of Australia’s governing body. An equivalent to the Federal Drug Administration endorsement in the United States, the TGA is also recognized outside of Australia by other governments around the world.

“The granting of this license reflects the level of dedication and effort from our Quality Team and the entire Pharmako staff,” continued Meppem. “Pharmako proudly export materials all around the world, and this full license justifies the trust international clients place in the quality of Australian manufacturing.”

Pharmako, the sister company of Gencor in the US, specializes in scientific research and innovative product development, including technologies that help to increase the solubility and bioavailability of lipophilic ingredients. Its other technologies include AquaCelle®, Compressible Powdered Oils, HydroCurc®, VeriSperse®, Quercetin and CWD and produces Levagen+® for Gencor.

For more information on Pharmako Biotechnologies, please visit https://www.pharmako.com.au/.

Leave a Reply